8-K: 3D Systems Reports Weak Q4 and Full Year 2023 Results, Announces Restructuring and Delayed 10-K Filing

3D Systems reported a 13.5% decrease in Q4 revenue and a 9.3% decrease in full-year revenue for 2023, citing significant headwinds in dental orthodontics and delayed customer capex investments, while also announcing a restructuring initiative and a delay in filing its annual report.

Summary

• 3D Systems' Q4 2023 revenue was $114.8 million, a 13.5% decrease compared to Q4 2022, primarily due to weakness in dental orthodontics and lower printer sales.
• The company's full-year 2023 revenue was $488.1 million, a 9.3% decrease compared to 2022, also impacted by the dental orthodontics market and slower printer sales.
• The Q4 2023 net loss was $300.4 million, or $2.30 per diluted share, largely due to a non-cash impairment of goodwill and other intangible assets.
• The full-year 2023 net loss was $370.4 million, or $2.85 per diluted share, also significantly impacted by the non-cash impairment.
• Adjusted EBITDA for Q4 2023 was a loss of $12.3 million, and for the full year 2023, it was a loss of $24.5 million.
• The company repurchased $135.1 million of its convertible senior notes for $100.6 million in December 2023, reducing outstanding debt by nearly 30%.
• 3D Systems ended 2023 with $331.5 million in cash and cash equivalents.
• The company is implementing a restructuring initiative to reduce costs and improve margins.
• 3D Systems expects relatively flat revenue for 2024, with a focus on achieving break-even or better adjusted EBITDA.
• The company is delaying the filing of its Annual Report on Form 10-K due to additional time needed to complete financial reporting close procedures.

Sentiment

Score: 3

Explanation: The document presents a challenging financial picture with significant revenue declines, substantial net losses, and a delay in filing the annual report. While there are some positives, such as improved gross margins and a strong cash position, the overall tone is negative due to the poor financial results and the need for restructuring.

Positives

• Gross profit margin increased in 2023 to 40.7% from 39.8% in 2022, indicating improved operational efficiencies.
• Non-GAAP gross profit margin also increased in 2023 to 41.1% from 39.8% in 2022.
• The company opportunistically reduced its outstanding debt by nearly 30% by repurchasing convertible senior notes at a substantial discount.
• 3D Systems has a strong cash position of $331.5 million, providing financial flexibility for restructuring and growth investments.
• The company is implementing a restructuring program to reduce costs and improve profitability.
• The company expects to achieve break-even or better adjusted EBITDA in 2024.

Negatives

• Q4 2023 revenue decreased by 13.5% compared to Q4 2022.
• Full-year 2023 revenue decreased by 9.3% compared to 2022.
• The dental orthodontics product line experienced a significant 39% revenue decline in 2023 compared to 2022.
• The company reported a substantial net loss of $300.4 million in Q4 2023 and $370.4 million for the full year 2023.
• Adjusted EBITDA was negative for both Q4 2023 and the full year 2023.
• The company is delaying the filing of its Annual Report on Form 10-K.

Risks

• The company faces ongoing macroeconomic and geopolitical volatility that is impacting customer spending.
• The dental orthodontics market continues to be a significant headwind for revenue.
• There is a risk that the restructuring initiatives may not be sufficient to achieve profitability.
• The delay in filing the 10-K could raise concerns among investors.
• The company's revenue is expected to be relatively flat in 2024, indicating continued challenges.
• The company is investing in Regenerative Medicine which is a high risk, high reward area.

Future Outlook

The company expects relatively flat revenue for 2024, with a focus on achieving break-even or better adjusted EBITDA. They anticipate sequential improvement throughout the year after a seasonally soft start in Q1. The company also expects continued benefit from in-sourcing and restructuring initiatives.

Management Comments

• Dr. Jeffrey Graves, president and CEO of 3D Systems, stated that the fourth quarter revenue results reflect significant headwinds from macroeconomic and geopolitical volatility.
• Dr. Graves noted that while customer-driven pre-sales activities accelerated as expected, the same could not be said for revenue.
• Dr. Graves believes the revenue issues are a market timing issue rather than a permanent trend in customer adoption rates.
• Dr. Graves highlighted that the most influential driver to their revenue performance was the dental orthodontic product line, which declined 39% from 2022 levels.
• Dr. Graves mentioned that the company has undertaken a comprehensive restructuring initiative to reduce costs and improve margins.
• Dr. Graves emphasized the company's strong balance sheet with over $300 million in cash and 0% interest debt not due until late 2026.
• Dr. Graves stated that the company will prioritize completion of its restructuring program by mid-year.
• Dr. Graves believes that the opportunities for growth in the additive manufacturing industry remain incredibly bright.

Industry Context

The announcement reflects a challenging period for the additive manufacturing industry, with 3D Systems experiencing headwinds similar to those faced by other companies in the sector. The company's focus on restructuring and cost reduction aligns with broader industry trends of seeking profitability amidst economic uncertainty. The company's focus on specific growth areas such as personalized healthcare and regenerative medicine also reflects a broader trend in the industry towards more specialized and high-value applications.

Comparison to Industry Standards

• While specific competitor results are not detailed in this document, the 39% decline in the dental orthodontics business is a significant underperformance compared to the broader market, which has seen growth in other areas of additive manufacturing.
• The company's focus on restructuring and cost optimization is a common response to economic pressures, similar to actions taken by other companies in the technology and manufacturing sectors.
• The company's investment in regenerative medicine is a high-risk, high-reward strategy that is not universally adopted by all competitors, indicating a more aggressive approach to future growth.
• The company's strong cash position is a positive differentiator compared to some competitors that may be facing liquidity challenges.
• The delay in filing the 10-K is a negative signal, as most companies in the sector are able to meet their reporting deadlines.

Stakeholder Impact

• Shareholders will be negatively impacted by the poor financial results and the delay in filing the annual report.
• Employees may be affected by the restructuring program, which includes headcount reductions.
• Customers may experience some disruption as the company undergoes restructuring.
• Suppliers may be impacted by the company's cost reduction efforts.
• Creditors may be concerned about the company's financial performance.

Next Steps

• The company will complete its restructuring program, which includes headcount reductions, site consolidations, and a reduction in external spending, largely by mid-year.
• The company will continue its most important development programs that are beginning to yield results.
• The company will host a conference call and webcast on February 28, 2024, to discuss the results.
• The company will file a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission.

Key Dates

Keywords

3D Printing, Additive Manufacturing, Financial Results, Restructuring, Dental Orthodontics, Healthcare Solutions, Industrial Solutions, EBITDA, Revenue, Net Loss, Impairment, Convertible Notes, Gross Margin